

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
yeast adj rna near10 inflammat\$	0

**Database:**

[US Patents Full-Text Database](#)  
[US Pre-Grant Publication Full-Text Database](#)  
[JPO Abstracts Database](#)  
[EPO Abstracts Database](#)  
[Derwent World Patents Index](#)  
[IBM Technical Disclosure Bulletins](#)

**Search:**

L5

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**
**DATE:** Tuesday, May 20, 2003    [Printable Copy](#)    [Create Case](#)

**Set Name   Query**  
side by side

**Hit Count   Set Name**  
result set

*DB=USPT,PGPB; PLUR=YES; OP=AND*

<u>L5</u>	yeast adj rna near10 inflammat\$	0	<u>L5</u>
<u>L4</u>	yeast adj rna near8 inflammat\$	0	<u>L4</u>
<u>L3</u>	l1 and L2	139	<u>L3</u>
<u>L2</u>	inflammation	36302	<u>L2</u>
<u>L1</u>	yeast adj rna	859	<u>L1</u>

END OF SEARCH HISTORY

=> d his

(FILE 'HOME' ENTERED AT 18:42:37 ON 20 MAY 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 18:42:53 ON 20 MAY 2003

L1 3942 S YEAST(W)RNA  
L2 3 S INFLAMMATION AND L1  
L3 3 DUP REM L2 (0 DUPLICATES REMOVED)

=> d bib ab 1-3 l3

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS  
AN 2001:730972 CAPLUS  
DN 135:267236  
TI **Yeast RNA** for treatment of inflammatory and  
inflammatory-related disorders  
IN Tkachuk, Zenoviy  
PA Biocell Laboratories, USA  
SO PCT Int. Appl., 66 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001073003	A1	20011004	WO 2001-US9590	20010326
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1278836	A1	20030129	EP 2001-926431	20010326
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRAI US 2000-534509 A 20000324  
WO 2001-US9590 W 20010326

AB The present invention concerns a compd. consisting of RNA, in particular RNA extd. from yeast, a pharmaceutical compn. comprising such RNA and a method for the treatment of inflammatory and inflammatory-related disorders comprising administering to a patient in need of such treatment a pharmaceutical compn. comprising an amt. effective to ameliorate the symptoms of **inflammation** or inflammatory-related disorder of RNA and a pharmaceutically acceptable vehicle, carrier, or diluent. The exogenous **yeast RNA** used in the present invention has a pronounced membrane-stabilizing action in a wide range of concns. At the same time, **yeast RNA** normalizes metab. of arachidonic acid and levels of its key metabolites, thromboxane and leukotriene. Its anti-inflammatory action is accompanied by normalization of the activity of NO-synthetase and anti-oxidant activity.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS  
AN 1994:153253 CAPLUS  
DN 120:153253  
TI Discriminating effects of a nucleotide-rich yeast extract, Probioticum, as an immunomodulator contrasted with actions in chronic immuno-inflammatory disease (adjuvant-induced arthritis) in rodents  
AU Burmeister, G.; Rainsford, K.D.

CS BMA Biomed. A.G., Augst, CH-4302, Switz.  
SO Inflammopharmacology (1991), 1(2), 161-83  
CODEN: IAOAES; ISSN: 0925-4692  
DT Journal  
LA English  
AB Following previous observations that **yeast RNA** (RNA) and nucleotide components exhibit immuno-stimulation in mice it was decided to det. the effects of a com.-available yeast ext. used for growth enhancement in domestic animals which is rich in RNA and nucleotides, ProbioticumR (Chemoforma AG, Augst, Switzerland) in std. immune models in mice and for effects on the progression of adjuvant-induced polyarthrititis in rats. Probioticum (PB) (1 g kg<sup>-1</sup> day<sup>-1</sup>) given p.o. for 6 wk to mice, which were also immunized during the last 6 wk with sheep red blood cells, produced activation of macrophages (detected by specific monoclonal antibodies) in cells of the bone marrow, increased antigen specific cells in the spleen, and a small redn. of thymus T-lymphocytes compared with control animals. High oral doses (up to 300-500 mg kg<sup>-1</sup> day<sup>-1</sup>) of PB given alone or with indomethacin p.o. during the inductive or established phases of adjuvant-induced arthritis failed to affect the course of this disease. Thus, the immunol. properties of PB appear principally to involve macrophage- and B-cell activation, with some possible minor alterations in T-cell activity. The immunol. effects of PB do not appear to be important for the prevention of adjuvant arthritis nor do they influence the prostaglandin-dependent components of the disease influenced by indomethacin.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS  
AN 1972:21579 CAPLUS  
DN 76:21579  
TI Diminution of iron-59 incorporation into red cells. Effect of abscess and exogenous RNA in vivo  
AU Rigby, P. G.; Zacharia, L. A.  
CS Coll. Med., Univ. Nebraska, Omaha, NE, USA  
SO Journal of Medicine (Westbury, NY, United States) (1971), 2(1), 60-64  
CODEN: JNMDBO; ISSN: 0025-7850  
DT Journal  
LA English  
AB The percentage of iron-59 [14596-12-4] incorporated into circulating erythrocytes in mice was decreased in animals with turpentine abscess, in animals given **yeast RNA** i.p., and in animals with turpentine abscess given **yeast RNA**. The ratio of the amt. of <sup>59</sup>Fe in the total blood compared to liver plus spleen decreased.

=>